Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway

被引:18
|
作者
Wang, Qi [1 ]
Wu, Hua [1 ]
Wu, Qingquan [1 ]
Zhong, Sheng [1 ,2 ]
机构
[1] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Thorac Surg, Huaian, Peoples R China
[2] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Thorac Surg, 1 Huanghe West Rd, Huaian 223000, Peoples R China
关键词
berberine; CCNE2; KIF20A; nonsmall cell lung cancer; PI3K/AKT pathway; IDENTIFICATION; EXPRESSION; SIGNATURE; THERAPY; GROWTH; POOR;
D O I
10.1002/ddr.22061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Nonsmall cell lung cancer (NSCLC) is the main type of lung cancer, accounting for approximately 85%. Berberine (BBR), a commonly used traditional Chinese medicine, has been reported to exhibit a potential antitumor effect in various cancers. In this research, we explored the function of BBR and its underlying mechanisms in the development of NSCLC.Methods: Cell Counting Kit-8 (CCK-8), 5-ethynyl-20-deoxyuridine (EdU), colony formation assays, flow cytometry, and transwell invasion assay were employed to determine cell growth, the apoptotic rate, cell invasion of NSCLC cells, respectively. Western blot was applied for detecting the protein expression of c-Myc, matrix metalloprotease 9 (MMP9), kinesin family member 20A (KIF20A), cyclin E2 (CCNE2), and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway-related proteins. Glycolysis was evaluated by detecting glucose consumption, lactate production, and adenosine triphosphate/adenosine diphosphate (ATP/ADP) ratio with the matched kits. Real-time quantitative polymerase chain reaction (RT-qPCR) was conducted to analyze the level of KIF20A and CCNE2. Tumor model was established to evaluate the function of BBR on tumor growth in NSCLC in vivo. In addition, immunohistochemistry assay was employed to detect the level of KIF20A, CCNE2, c-Myc, and MMP9 in mice tissues.Results: BBR exhibited suppressive effects on the progression of NSCLC, as evidenced by inhibiting cell growth, invasion, glycolysis, and facilitating cell apoptosis in H1299 and A549 cells. KIF20A and CCNE2 were upregulated in NSCLC tissues and cells. Moreover, BBR treatment significantly decreased the expression of KIF20A and CCNE2. KIF20A or CCNE2 downregulation could repress cell proliferation, invasion, glycolysis, and induce cell apoptosis in both H1299 and A549 cells. The inhibition effects of BBR treatment on cell proliferation, invasion, glycolysis, and promotion effect on cell apoptosis were rescued by KIF20A or CCNE2 overexpression in NSCLC cells. The inactivation of PI3K/AKT pathway caused by BBR treatment in H1299 and A549 cells was restored by KIF20A or CCNE2 upregulation. In vivo experiments also demonstrated that BBR treatment could repress tumor growth by regulating KIF20A and CCNE2 and inactivating the PI3K/AKT pathway.Conclusion: BBR treatment showed the suppressive impact on the progression of NSCLC by targeting KIF20A and CCNE2, thereby inhibiting the activation of the PI3K/AKT pathway.
引用
收藏
页码:907 / 921
页数:15
相关论文
共 50 条
  • [41] Chloroquine Suppresses Colorectal Cancer Progression via Targeting CHKA and PFKM to inhibit the PI3K/AKT and the Effect
    Liu, Yanqing
    Zhu, Yongping
    Gu, Liwei
    Li, Kexin
    Ma, Ang
    Liu, Li
    Meng, Yuqing
    Zhang, Junzhe
    Shen, Shengnan
    Shi, Qiaoli
    Liu, Dandan
    Zhang, Xinwei
    Zhang, Shujie
    Chai, Xin
    Gao, Peng
    Xing, Jiale
    Wang, Yaxu
    Chen, Honglin
    Liu, Rui
    Du, Qingfeng
    Liu, Haitao
    Dai, Lingyun
    Wang, Jigang
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2025, 21 (04): : 1619 - 1631
  • [42] Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway
    Zhang, Yan
    Chen, Peisheng
    Yin, Wei
    Ji, Ye
    Shen, Qin
    Ni, Qingfeng
    HUMAN PATHOLOGY, 2018, 72 : 107 - 116
  • [43] Knockdown of FUT11 inhibits the progression of gastric cancer via the PI3K/AKT pathway
    Cao, Wenpeng
    Zeng, Zhirui
    Lan, Jinzhi
    Yang, Yushi
    Lu, Min
    Lei, Shan
    HELIYON, 2023, 9 (07)
  • [44] Claudin-14 promotes colorectal cancer progression via the PI3K/AKT/mTOR pathway
    Qiao, Tian-Yu
    Yuan, Zi-Ming
    Ma, Tian-Yi
    Hu, Han-Qing
    Zhu, Yi-Hao
    Zhang, Wei-Yuan
    Zhang, Qian
    Huang, Rui
    Tang, Qing-Chao
    Wang, Gui-Yu
    Wang, Xi-Shan
    NEOPLASMA, 2021, 68 (05) : 947 - +
  • [45] Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway
    Xu, Tao
    Rao, Ting
    Yu, Wei-Ming
    Ning, Jin-Zhuo
    Yu, Xi
    Zhu, Shao-Ming
    Yang, Kang
    Bai, Tao
    Cheng, Fan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2021, 47 (06)
  • [46] SLC1A3 promotes gastric cancer progression via the PI3K/AKT signalling pathway
    Xu, Liyi
    Chen, Jiamin
    Jia, Litao
    Chen, Xiao
    Moumin, Faycal Awaleh
    Cai, Jianting
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (24) : 14392 - 14404
  • [47] MFAP2 promotes the malignant progression of gastric cancer via activating the PI3K/AKT signaling pathway
    Guo, Peng
    Dai, Ting
    Jin, Xiaohu
    Wu, Hao
    Qiu, Shengkui
    Tang, Chong
    Feng, Shichun
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2025,
  • [48] RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway
    Guo, Linfa
    Zhao, Yiqiao
    Bai, Xiaojie
    Wang, Xiaolong
    Tuoheti, Kuerban
    Cao, Yuanfei
    Zuo, Yingtong
    Zhang, Xinhua
    Liu, Tongzu
    JOURNAL OF CELLULAR PHYSIOLOGY, 2025, 240 (01)
  • [49] Erianin inhibits human lung cancer cell growth via PI3K/Akt/mTOR pathway in vitro and in vivo
    Zhang, Hui-qiong
    Xie, Xiao-fang
    Li, Gang-min
    Chen, Jun-ren
    Li, Meng-ting
    Xu, Xin
    Xiong, Qiu-yun
    Chen, Guan-ru
    Yin, Yan-peng
    Peng, Fu
    Chen, Yan
    Peng, Cheng
    PHYTOTHERAPY RESEARCH, 2021, 35 (08) : 4511 - 4525
  • [50] LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway
    Liu, Chunfeng
    Ren, Lei
    Deng, Jun
    Wang, Songping
    BIOSCIENCE REPORTS, 2019, 39